89Zr-DFO-YS5

89Zr-DFO-YS5 is an investigational CD46-targeted radiopharmaceutical developed for immunoPET imaging in patients with prostate cancer. It consists of the fully human monoclonal antibody YS5, which specifically targets the CD46 antigen, conjugated to the radioisotope zirconium-89 (89Zr) via the chelator desferrioxamine (DFO). CD46 is a cell surface protein that is significantly overexpressed in metastatic castration-resistant prostate cancer (mCRPC), including both adenocarcinoma and small-cell neuroendocrine carcinoma (SCNC) phenotypes. The agent is designed to detect CD46-positive malignancies, serving as a diagnostic tool and a potential companion biomarker for CD46-targeted therapies such as antibody-drug conjugates (e.g., FOR46). The development and clinical evaluation of 89Zr-DFO-YS5 are led by Robert Flavell, MD, PhD, at the University of California, San Francisco (UCSF).

Other names

89Zr-YS5zirconium-89-desferrioxamine-YS5zirconium89-desferrioxamine-YS5zirconium 89-desferrioxamine-YS5CD46-targeted immunoPET agentCD-46-targeted immunoPET agentCD 46-targeted immunoPET agent